SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers. Lu Z, Mao W, Yang H, Santiago-O'Farrill JM, et al. J Clin Invest 2022;132.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lu Z, Mao W, Yang H, Santiago-O'Farrill JM, et al. SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers. J Clin Invest 2022;132.
PMID: 35642638